HONG KONG--(Marketwire - Jun 8, 2012) - Today, [ www.BrightonMarkets.com ] announced new reports highlighting Amarin Corporation plc (ADR) (NASDAQ: [ AMRN ]) and Warner Chilcott Plc (NASDAQ: [ WCRX ]). Gain market insight with full analysis and research downloads available at [ www.BrightonMarkets.com/index.php?coa=AMRN&cob=WCRX ].

With markets in correction mode, investors are looking to quantify an accurate model, weighing positives and negatives of the months ahead. Upcoming negative pressures include China's slowdown, the European recession, the end of the Fed's Operation Twist stimulus program, continued geopolitical risks, election uncertainty, and potential 2013 budget bombshell of tax hikes and spending cuts. Meanwhile, positive offsets are driven by central banks (particularly China) cutting rather than hiking rates, deceleration in fuel and food prices, increase in consumer sentiment and resulting retail sales, signs of improvement in housing sales and new strength in auto production schedules.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Brighton Markets is releasing new coverage on Amarin Corporation plc (ADR) for its current position within the healthcare industry. Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. The full research report on Amarin Corporation plc (ADR) (NASDAQ: [ AMRN ]) is available here: [ www.BrightonMarkets.com/index.php?coa=AMRN ].

Brighton Markets has released research on Warner Chilcott Plc for its changing role within the healthcare industry. Warner Chilcott Public Limited Company is a specialty pharmaceutical company. It is focused on the women's healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America. It is an integrated company with internal resources focused on the development, manufacture and promotion of its products. The full research report on Warner Chilcott Plc (NASDAQ: [ WCRX ]) is available here: [ www.BrightonMarkets.com/index.php?cob=WCRX ].

About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.